CN102939299B - 凝血因子的纯化 - Google Patents

凝血因子的纯化 Download PDF

Info

Publication number
CN102939299B
CN102939299B CN201180006396.5A CN201180006396A CN102939299B CN 102939299 B CN102939299 B CN 102939299B CN 201180006396 A CN201180006396 A CN 201180006396A CN 102939299 B CN102939299 B CN 102939299B
Authority
CN
China
Prior art keywords
gla
factor
buffer
sample
immunoaffinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180006396.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102939299A (zh
Inventor
J.R.布杰尔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN102939299A publication Critical patent/CN102939299A/zh
Application granted granted Critical
Publication of CN102939299B publication Critical patent/CN102939299B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180006396.5A 2010-01-18 2011-01-18 凝血因子的纯化 Expired - Fee Related CN102939299B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10150980.0 2010-01-18
EP10150980 2010-01-18
US29701110P 2010-01-21 2010-01-21
US61/297011 2010-01-21
PCT/EP2011/050594 WO2011086197A1 (en) 2010-01-18 2011-01-18 Purification of blood coagulation factors

Publications (2)

Publication Number Publication Date
CN102939299A CN102939299A (zh) 2013-02-20
CN102939299B true CN102939299B (zh) 2016-04-20

Family

ID=42173365

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180006396.5A Expired - Fee Related CN102939299B (zh) 2010-01-18 2011-01-18 凝血因子的纯化

Country Status (8)

Country Link
US (1) US9896677B2 (https=)
EP (1) EP2526115B1 (https=)
JP (1) JP6250931B2 (https=)
KR (1) KR20120118028A (https=)
CN (1) CN102939299B (https=)
BR (1) BR112012017696A2 (https=)
RU (1) RU2012133474A (https=)
WO (1) WO2011086197A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2526115B1 (en) * 2010-01-18 2018-08-01 Novo Nordisk Health Care AG Purification of blood coagulation factors
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
AU2013364043B2 (en) 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
US10643423B2 (en) 2016-09-23 2020-05-05 Sg Gaming, Inc. System and digital table for binding a mobile device to a position at the table for transactions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633350A (en) * 1994-02-28 1997-05-27 Immuno Aktiengesellschaft Method for the isolation and purification of vitamin K-dependent proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258938B1 (en) 1983-10-28 2001-07-10 Ne Medical Center Hospital, Inc. Method for the purification and isolation of blood clotting proteins using conformation specific antibodies
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
ATE195877T1 (de) 1991-03-01 2000-09-15 Rhone Poulenc Rorer Int Herstellung von faktor-ix
IT1262899B (it) 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
SE0000675D0 (sv) 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
RU2364626C2 (ru) 2003-03-18 2009-08-20 Ново Нордиск Хелт Кэр Аг Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x
ES2395544T3 (es) 2004-12-23 2013-02-13 Novo Nordisk Health Care Ag Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés
EP1963506B1 (en) 2005-12-02 2010-10-27 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
WO2008104372A1 (en) 2007-02-28 2008-09-04 Baxter International Inc. Method for the purification of recombinant blood coagulation factor ix enriched in sulfated and/or phosphorylated molecules
AU2009324204B2 (en) 2008-12-02 2014-10-16 Novo Nordisk Health Care Ag Polypeptide purification
EP2526115B1 (en) * 2010-01-18 2018-08-01 Novo Nordisk Health Care AG Purification of blood coagulation factors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633350A (en) * 1994-02-28 1997-05-27 Immuno Aktiengesellschaft Method for the isolation and purification of vitamin K-dependent proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Affinity purification of biologically active and inactive forms of recombinant human protein C produced in porcine mammary gland;Kevin E. Van Cott et al.;《Journal of molecular recognition》;19961231;第9卷(第5-6期);摘要，第408页左栏第1段，第409页左栏第3段、右栏第2段，第410页右栏第1段，第412页右栏第3段，第413页左栏第4段，图1-图5及图5注解 *
Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1，the Viatmin K 2,3-expoxide-reducing enzyme of the vitamin K cycle;Nadeem Wajih et al.;《The journal of biological chemistry》;20050909;第280卷(第36期);第31603页左栏第2段至右栏第1段，第31604页右栏第1段，第31605页右栏第1段，第31606页左栏第1段，第31607页左栏第2段，图1及图1注解 *

Also Published As

Publication number Publication date
RU2012133474A (ru) 2014-02-27
US20130034896A1 (en) 2013-02-07
US9896677B2 (en) 2018-02-20
JP2013517259A (ja) 2013-05-16
BR112012017696A2 (pt) 2017-10-03
EP2526115B1 (en) 2018-08-01
EP2526115A1 (en) 2012-11-28
WO2011086197A1 (en) 2011-07-21
KR20120118028A (ko) 2012-10-25
JP6250931B2 (ja) 2017-12-20
CN102939299A (zh) 2013-02-20

Similar Documents

Publication Publication Date Title
Camire et al. Enhanced γ-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide
JP5788803B2 (ja) ポリペプチド精製
AU2011234521B2 (en) A process for purifying Vitamin K dependent proteins such as coagulation factor IX
EP2504349B1 (en) Method of purifying pegylated proteins
KR20110005862A (ko) 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
CN102939299B (zh) 凝血因子的纯化
AU2008254522B2 (en) Method for producing mature VWF from VWF pro-peptide
CA2684885A1 (en) Preparative purification process for human furin
JP2010527588A5 (https=)
JP2024180602A (ja) 第ｘａ因子及び誘導体を調製するための組成物及び方法
AU2017381677B2 (en) Chromatographic method for collecting blood coagulation factor VII with high yield
ES2792473T3 (es) Método para purificar proteínas PEGiladas
AU2012216707A1 (en) Method for Producing Mature VWF From VWF Pro-peptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160420

Termination date: 20190118

CF01 Termination of patent right due to non-payment of annual fee